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Both Low and High 24-Hour
Diastolic Blood Pressure Are
Associated With Worse Cognitive
Performance in Type 2 Diabetes:
The Maastricht Study
Diabetes Care 2015;38:1473–1480 | DOI: 10.2337/dc14-2502
OBJECTIVE
Hypertension and diabetes are both risk factors for cognitive decline, and indi-
vidualswith bothmight have an especially high risk.We therefore examined linear
and nonlinear (quadratic) associations of 24-h blood pressure (BP) with cognitive
performance in participants with and without type 2 diabetes. We also tested the
association of nocturnal dipping status with cognitive performance.
RESEARCH DESIGN AND METHODS
This study was performed as part of theMaastricht Study, an ongoing population-
based cohort study. Cross-sectional associations of 24-h BP (n = 713, of whom 201
had type 2 diabetes) and nocturnal dipping status (n = 686, ofwhom196 had type 2
diabetes) with performance on tests for global cognitive functioning, information
processing speed, verbal memory (immediate and delayed word recall), and re-
sponse inhibition were tested using linear regression analysis and adjusted for
demographics, vascular risk factors, cardiovascular disease, depression, and lipid-
modifying and antihypertensive medication use.
RESULTS
After full adjustment, we found quadratic (inverted U-shaped) associations of
24-h diastolic blood pressure (DBP) with information processing speed (b for
quadratic term = 20.0267, P < 0.01) and memory (immediate word recall: b =
20.0180, P < 0.05; delayed word recall: b =20.0076, P < 0.01) in participants with
diabetes, but not in those without. No clear pattern was found for dipping status.
CONCLUSIONS
This study shows that both low and high 24-h DBP are associated with poorer
performance on tests of information processing speed and memory in individuals
with type 2 diabetes.
Type 2 diabetes is associated with cognitive decline and dementia (1,2), but the
pathological mechanisms underlying these associations are not yet clear. Proposed
mechanisms include the role of vascular risk factors, such as hypertension. Some
studies have shown an association of hypertension with cognitive dysfunction and
Alzheimer disease in individuals with diabetes (3,4). In addition, diabetes and hy-
pertension seem to interact in their effect on cognitive decline (5) and dementia (6),
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indicating that individuals with both di-
abetes and hypertension may have an
especially high risk of cognitive decline.
Other studies, however, did not confirm
these results (7,8).
Above-mentioned studies (5–8) used
office measurements as an estimate of
blood pressure (BP) exposure. However,
office BP measurement is less accurate
than 24-h ambulatory BP measurement
(ABPM) and cannot capture important
physiological phenomena such as the
normal decrease of BP during sleep (so-
called “dipping”). Indeed, ambulatory BP
has shown to be superior to office BP in
predicting progression of cerebrovascular
disease and cognitive decline (9). In addi-
tion, nondipping, i.e., the blunting of the
physiological BP reduction during sleep,
as well as extreme dipping, i.e., excessive
reduction in BP during sleep, have been
associated with cerebrovascular damage
and lower cognitive performance (10–
12). Nondipping is more prevalent in
type 2 diabetes (13), and as both diabetes
and abnormal dipping patterns havebeen
associated with lower cognitive perfor-
mance, one may speculate that individu-
als with diabetes who show abnormal
dipping in nocturnal BP are especially at
risk to develop cognitive impairment.
To our knowledge, there are no studies
to date that have addressed the question
of whether ambulatory BP and dipping
parameters are associated with multiple
cognitive domains in type 2 diabetes.
Therefore, we studied associations be-
tween 24-h ambulatory BP and cognitive
performance stratified by diabetes sta-
tus. Since previous studies have shown
quadratic relationships between BP and
cognitive functions (14,15), we examined
both linear and quadratic associations. In
addition, we examined the association of
nondipping and extreme dipping in BP
during sleep with cognitive performance
in individuals with and without type 2
diabetes. Based on the above, we hy-
pothesized that associations between
24-h ambulatory BP, nondipping, and ex-
treme dipping on the one hand and cog-
nitive functions on the other are stronger
in individuals with type 2 diabetes com-
pared with those without diabetes.
RESEARCH DESIGN AND METHODS
Study Population and Design
In this study, we used data from the
Maastricht Study, an observational, pro-
spective, population-based cohort study.
The rationale and methodology have
been described previously (16). In brief,
the study focuses on the etiology, path-
ophysiology, complications, and comor-
bidities of type 2 diabetes and is
characterized by an extensive phenotyp-
ing approach. Eligible for participation
were all individuals aged between 40
and 75 years and living in the southern
part of the Netherlands. Participants
were recruited through mass media cam-
paigns and from the municipal registries
and the regional Diabetes Patient Registry
via mailings. Recruitment was stratified
according to known type 2 diabetes sta-
tus for reasons of efficiency. The present
report includes cross-sectional data from
the first 866 participants, who completed
the baseline survey between November
2010 and March 2012. The examinations
of each participant were performed
within a time window of 3 months. The
study has been approved by the insti-
tutional medical ethics committee
(NL31329.068.10) and the Netherlands
Health Council under the Dutch “Law for
Population Studies” (permit 131088-
105234-PG). All participants gave written
informed consent.
Glucose Metabolism Status
To determine glucose metabolism, all
participants (except those who use insu-
lin) underwent a standardized 7-point
oral glucose tolerance test after an over-
night fast as previously described (16).
Glucose metabolism was defined accord-
ing to the World Health Organization
2006 criteria into normal glucose toler-
ance (NGT), impaired fasting glucose
(IFG), impaired glucose tolerance (IGT),
and type 2 diabetes (17). Additionally, in-
dividuals without type 1 diabetes and on
diabetes medication were considered as
having type2diabetes (16). For this study,
we defined having either IFG or IGT as
impaired glucose metabolism (IGM).
ABPMs
Ambulatory BP was measured with am-
bulatory 24-h BP monitoring (WatchBP
O3; Microlife AG, Widnau, Switzerland).
Cuffs were applied to the participants’
nondominant arm. Measurements were
programmed for every 15min during day-
time (08:00 A.M.–11:00 P.M.) andevery 30min
during the night (11:00 P.M.–08:00 A.M.),
for a total of 24 h. As quality criteria,
mean 24-h BP measurements were
only calculated if there were .14 valid
measurements at daytime and .7 valid
measurements at night, based on recom-
mendations of the British Hypertension
Society (18,19). Mean 24-h systolic blood
pressure (SBP) and diastolic blood pres-
sure (DBP) were calculated based on
hourly averages (20). Twenty four–hour
pulse pressure (PP) was defined as 24-h
SBP minus 24-h DBP and mean arterial
pressure (MAP) as 24-h DBP plus (0.4123
24-h PP) (21). Mean daytime and night-
time SBP and DBP were calculated using
measurements between 09:00 A.M. and
09:00 P.M. (.14 valid measurements
were required) and between 01:00 A.M.
and 06:00 A.M. (.7 valid measurements
were required), respectively (18). The rel-
ative difference between mean daytime
and mean nighttime BP levels was com-
puted and expressed as a percentage of
the daytime BP average. Participants
were classified as nondippers when the
nocturnal drop in SBP or DBP was,10%
of themean daytime level and as extreme
dippers when the nocturnal drop was
$20% (22). In all other cases, participants
were assigned to the dipper category.
Assessment of Cognitive Function
A concise battery (30 min) of cognitive
tests was used to assess cognitive func-
tioning (16). An a priori selection of these
cognitive tests was used in the current
study. Global cognitive functioning was
measured by the Mini-Mental State Ex-
amination (23). Verbal memory was as-
sessed with the Visual Verbal Word
Learning Test (24). In this test, 15 words
are presented in five subsequent trials,
followed by a recall phase immediately
after each trial (immediate recall) and a
delayed recall phase 20 min thereafter
(delayed recall). Response inhibition was
measured with the Stroop Color Word
Test (25,26). The variable of interest was
the interference measure expressed in
seconds. The Letter-Digit Substitution
Test (27) was used to measure informa-
tion processing speed. Participants were
instructed to match digits to letters as
quickly as possible within 90 s.
Covariates
History of cardiovascular disease, diabetes
duration, smoking status (never, former,
or current), and alcohol consumption
were assessed by questionnaire (16,28).
Alcohol consumption was classified into
three categories as described elsewhere
(28). Lipid-modifying, antihypertensive,
and glucose-lowering medication use
were assessed during a medication
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interview where generic name, dose,
and frequency were registered (16).
Waist circumference, glycosylated he-
moglobin A1c (HbA1c), total and HDL cho-
lesterol, creatinine, and triglycerides
were determined as described else-
where (16). Estimated glomerular filtra-
tion rate (eGFR) was estimated using the
CKD-EPI (Chronic Kidney Disease Epide-
miology Collaboration) equation based
on serum creatinine (29). Vibration per-
ception thresholds (VPTs) were tested
with a Horwell Neurothesiometer (Scien-
tific Laboratory Supplies, Nottingham,
U.K.) in order to assess the presence of
nerve damage due to diabetic neuropa-
thy. VPTs were tested three times at the
distal phalanx of the hallux of the right
and left foot (16). We used the mean
value of the two feet for analyses. Level
of education was assessed during the
cognitive assessment and was classified
into eight categories commonly used in
the Netherlands (30). Three groups were
made for educational level: low (level 1–
3), intermediate (level 4–6), and high
(level 7–8) (28). Presence of depression
was assessed by the Mini International
Neuropsychiatric Interview (16,31).
Statistical Analysis
Analyses were conducted using SPSS ver-
sion 20 for Mac OSX (SPSS, Inc.). Differ-
ences between group characteristics
were tested using independent samples
Student t test for continuous variables
andx2 tests for categorical variables.Mul-
tiple linear regression analysis was used
to estimate the association between am-
bulatory BP and cognitive performance,
stratified by diabetes status. Both linear
and quadratic (squared) 24-h BP terms
were included in the models. To control
for multicollinearity, linear terms were
centered around the mean before form-
ing the quadratic term by subtracting the
mean value of the sample from the raw
values. When the quadratic term was not
significantly associatedwith any cognitive
measure, it was dropped from the mod-
els. For analyses with dipping status,
three groups were made: dippers (refer-
ence group), nondippers, and extreme
dippers (see above). Associations were
first adjusted for age, sex, and educa-
tional level (model 1), and then for
smoking, alcohol, waist circumference,
total cholesterol-to-HDL cholesterol ratio,
triglyceride level, antihypertensive medi-
cation use, lipid-modifying medication
use, eGFR, cardiovascular disease, and
depression (model 2). Response inhibi-
tion scores were log transformed before
regression analysis because they were
positively skewed. A two-sided P value
of ,0.05 was considered statistically
significant.
RESULTS
Of the 866 participants included in the
Maastricht Study, four individuals with
type 1 diabetes and four participants
who did not have a cognitive assessment
were excluded. Of the remaining 858 par-
ticipants, we additionally excluded indi-
viduals with missing data on the
independent variables, i.e., 24-h BP (n =
88) and dipping parameters (n = 116), or
with missing data on the potential con-
founders (n = 57). This resulted in 713
participants (512 without and 201 with
diabetes) for analyses with 24-h BP and
686 participants (490 without and 196
with diabetes) for dipping variables. Par-
ticipants who were excluded due to miss-
ing values were more often low educated
and more likely to be depressed, to be
current smokers, and to use glucose-
loweringmedication (particularly insulin).
There were no differences in other base-
line characteristics (data not shown).
Table 1 shows the general character-
istics of the 713 individuals included strat-
ified by diabetes status. Of these, 201
participants (28.2%) had type 2 diabetes,
of whom 32 (15.9%) were newly diag-
nosed at study entry, 119 (59.2%) used
oral medication (of whom 2 participants
also used glucagon-like peptide 1 recep-
tor agonists) and 37 (18.4%) used insulin
(of whom 27 also used oral medication).
Of the 512 participants without dia-
betes, 118 participants (16.5% of the to-
tal sample) had IGM. There were no
significant differences in performance
on any cognitive measure between par-
ticipants with IGM and those with NGT
after adjustment for age and sex (P .
0.10 for all measures) (data not shown).
Twenty Four–Hour SBP, DBP, and
Cognitive Performance
Table 2 shows adjusted linear and qua-
dratic associations between 24-h BP and
cognitive measures. In participants with-
out diabetes, no significant linear or qua-
dratic associations between 24-h SBP or
DBP and cognitive measures were ob-
served (Table 2, models 1 and 2). In par-
ticipantswith type 2 diabetes, no linear or
quadratic associations were found be-
tween 24-h SBP and cognitive perfor-
mance after adjustment for potential
confounders (models 1 and 2). However,
24-h DBP showed quadratic associations
with information processing speed, im-
mediate anddelayed recall, and response
inhibition in model 1 (Table 2). After full
adjustment, these associations remained
significant, except for response inhibition
(P = 0.074). These associations indicated
that individuals with diabetes and
either a low or high 24-h DBP performed
more poorly on tasks for speed, as well as
for immediate and delayed word recall,
than those with a midrange DBP (an in-
verted U-shaped relation). Additional
analyses showed that associations of
24-h SBP and DBP with cognitive perfor-
mance were similar in participants with
IGM and NGT (data not shown).
Furthermore, quadratic associations
of 24-h DBPwith information processing
speed and memory were significantly
different in participants with diabetes
compared with those without, for infor-
mation processing speed (P for interac-
tion between diabetes and quadratic
24-h DBP = 0.001), immediate word recall
(P for interaction = 0.021), and delayed
word recall (P for interaction = 0.009) in
the fully adjusted model (model 2). These
interactions are depicted in Fig. 1.
Further analyses of daytime (available
for 495 participants without and 198with
diabetes) and nighttime (available for 500
participants without and 197 with diabe-
tes) SBP and DBP separately showed no
significant linear or quadratic associations
of daytime or nighttime SBP with cogni-
tive performance in individuals without
diabetes after full adjustment for poten-
tial confounders (data not shown). In in-
dividuals with diabetes, we found a linear
association between daytime SBP and in-
formation processing speed (P , 0.05),
but no other significant associations. In
contrast, both quadratic daytime and
quadratic nighttime DBP were signifi-
cantly associated with information pro-
cessing speed, and immediate and
delayed word recall (P , 0.05) after full
adjustment for potential confounders in
individualswith diabetes, but not in those
without (data not shown).
Twenty Four–Hour PP, MAP, and
Cognitive Performance
In participants without diabetes, neither
24-h PP nor 24-h MAP was significantly
care.diabetesjournals.org Spauwen and Associates 1475
associated with cognitive performance
(Supplementary Table 1). In participants
with diabetes, we found no significant as-
sociations between 24-h PP and cognitive
measures, but the quadratic term of 24-h
MAP was significantly associated with in-
formation processing speed (model 1:
b for quadratic term = 20.0159, P =
0.004; model 2: b = 20.0126, P = 0.026).
The quadratic association of 24-h MAP
with delayed word recall was significant
in model 1 (b = 20.0039, P = 0.040)
but became nonsignificant after full ad-
justment (b = 20.0035, P = 0.069). The
quadratic association with immediate
word recall was not significant (model 1:
b = 20.0108, P = 0.077; model 2:
b = 20.0064, P = 0.294). Since another
calculation of MAP (24-h DBP +
1/3 * [24-h SBP 2 24-h DBP]) has been
used previously in other studies, we
performed additional analyses with
this definition of MAP. Results showed
that the quadratic association of 24-h
MAP with delayed word recall in-
creased slightly and became significant
in participants with diabetes (model 2:
b = 20.0042, P = 0.042). Other associ-
ations remained largely unchanged
(data not shown).
Dipping and Cognitive Performance
Supplementary Table 2 shows the re-
sults of the associations between
dipping status and cognitive perfor-
mance stratified by diabetes status. In
participants without diabetes, nondip-
ping in DBP was associated with slower
information processing speed after full
adjustment for potential confounders
(model 2: b =22.713, P = 0.029). Other
dipping parameters were not associ-
ated with cognitive performance (Sup-
plementary Table 2). In participants
with diabetes, extreme dipping in SBP
was associated with worse global cog-
nitive functioning (model 2: b =
20.973, P = 0.012). Extreme dipping
in DBP was associated with a decreased
delayed word recall in participants with
diabetes, but only after full adjustment
Table 1—Baseline characteristics of the 713 participants stratified by diabetes status
Characteristic No T2D (n = 512) T2D (n = 201) P value*
Age, mean (SD) 58.3 (8.5) 63.7 (7.0) ,0.001
Male sex, n (%) 248 (48.4) 145 (72.1) ,0.001
Educational level, low/middle/high, n (%) 57/201/254 52/102/47 ,0.001
(11.1/39.3/49.6) (25.9/50.7/23.4)
Smoking status, never/former/current, n (%) 180/257/75 43/132/26 0.001
(35.2/50.2/14.6) (21.4/65.7/12.9)
Alcohol consumption, none/low/high, n (%) 65/275/172 57/103/41 ,0.001
(12.7/53.7/33.6) (28.4/51.2/20.4)
Waist circumference (cm), mean (SD) 93.6 (11.8) 106.0 (13.0) ,0.001
Total cholesterol-to-HDL cholesterol ratio, mean (SD) 4.24 (1.29) 4.15 (1.10) 0.34
Triglycerides (mmol/L), median (IQR) 1.13 (0.79–1.58) 1.63 (1.12–2.27) ,0.001**
Antihypertensive medication use, n (%) 141 (27.5) 138 (68.7) ,0.001
Lipid-modifying medication, n (%) 100 (19.5) 157 (78.1) ,0.001
HbA1c (%), mean (SD) 5.7 (0.4) 6.9 (0.8) ,0.001
HbA1c (mmol/mol), mean (SD) 38.3 (4.0) 51.8 (8.8) ,0.001
Glucose-lowering medication use, none/oral/insulin, n (%) 45/119/37
d (22.4/59.2/18.4)
Diabetes duration (years), median (IQR) d 7 (3.0–11.0)
eGFR (mL/min/1.73 m2), mean (SD) 85.7 (14.1) 82.5 (15.0) 0.01
VPT (V), median (IQR)§ 9.2 (6.3–13.5) 13.4 (9.8–20.8) ,0.001**
Cardiovascular disease, n (%) 63 (12.3) 61 (30.3) ,0.001
Depression, n (%) 15 (2.9) 11 (5.5) 0.10
SBP 24 h (mmHg), mean (SD) 117.7 (11.9) 123.7 (12.8) ,0.001
DBP 24 h (mmHg), mean (SD) 74.2 (7.3) 73.9 (7.2) 0.58
PP 24 h (mmHg), mean (SD) 43.5 (8.0) 49.8 (10.3) ,0.001
MAP 24 h (mmHg), mean (SD) 92.2 (8.6) 94.4 (8.5) 0.002
Dipper status SBP, dippers/nondippers/extreme dippers, n (%) 258/174/58 91/89/16 0.04
(52.7/35.5/11.8) (46.4/45.4/8.2)
Dipper status DBP, dippers/nondippers/extreme dippers, n (%) 212/56/222 72/52/72 ,0.001
(43.3/11.4/45.3) (36.7/26.5/36.7)
Global cognitive functioning (score), mean (SD) 29.1 (1.1) 28.5 (1.4) ,0.001
Information processing speed (number of digits), mean (SD) 50.4 (9.1) 44.2 (8.8) ,0.001
Immediate word recall (number of words), mean (SD) 47.2 (9.2) 40.7 (9.4) ,0.001
Delayed word recall (number of words), mean (SD) 10.0 (2.8) 8.4 (2.9) ,0.001
Response inhibition (s), median (IQR) 39.2 (30.8–49.7) 52.2 (38.8–70.3) ,0.001**
For global cognitive functioning, information processing speed, immediate word recall, and delayed word recall, higher scores indicate better
performance. For response inhibition, lower scores indicate better performance. T2D, type 2 diabetes. *P for difference between groups. **P values
are derived from independent samples Student t tests with log-transformed outcomes. §Available for 381 participants without diabetes and 142
with diabetes.
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for confounders (model 2: b = 20.928,
P = 0.038).
Post Hoc Analyses
We further adjusted the significant qua-
dratic associations of 24-h DBP with
information processing speed, and
immediate and delayed word recall in
participants with diabetes for the diabetes-
related variables HbA1c level, diabetes
duration (available for 168 individuals
with diabetes), and glucose-lowering
medication use (yes/no) (data not
shown). These associations did not
change after further adjustment. Since
diabetic neuropathy may affect associa-
tions of BP with cognitive performance,
we also adjusted these associations in a
separate model for VPTs (available for
142 individualswith diabetes) as amarker
for nerve damage due to diabetic neurop-
athy. Additional adjustment for VPTs
(model 2 + adjustment for VPTs) did not
materially change the associations (data
not shown).
Last, we examined associations of
24-h SBP and DBP variability, measured
by the weighted 24-h SD (i.e., the mean
of the daytime and nighttime SD, each
weighted for the duration of day and
night periods, respectively) (32), with
cognitive performance. Mean weighted
24-h SD of SBP and DBP were signifi-
cantly higher in the group with diabetes
(mean weighted 24-h SD of SBP [SD] =
12.5 mmHg [3.1]; mean weighted 24-h
SD of DBP [SD] = 9.8 mmHg [2.9]) com-
pared with the group without diabetes
(mean weighted 24-h SD of SBP [SD] =
11.5 mmHg [3.0]; mean weighted 24-h
SD of DBP [SD] = 9.0 mmHg [2.6]) (P ,
0.01 for both). No significant linear or qua-
dratic associations between weighted
24-h SBP SD and cognitive performance
were observed in either group (Supple-
mentary Table 3). We found a linear asso-
ciation between weighted 24-h DBP SD
and global cognitive functioning in the
group without diabetes, but no other sig-
nificant associations in either group (Sup-
plementary Table 3).
Sensitivity Analyses
Z scores for 24-h DBP were calculated for
the groupwith diabetes. Participantswith
z scores.3 or,23 were excluded from
analyses to examine whether our results
were influenced by extreme observa-
tions. One participant had a z score .3
but exclusion of this participant did not
change the results (data not shown).
CONCLUSIONS
In this study, individuals with type 2 di-
abetes with either a low or high 24-h
DBP performed worse on cognitive tests
of information processing speed and
verbal memory compared with those
with a midrange 24-h DBP (inverted
U-shaped relationship), whereas these
associations were not found in individu-
als without diabetes. These associations
were also found for both daytime and
nighttime diastolic BP, separately. In
contrast, we found no associations of
24-h SBP with cognitive performance
and no consistent associations of 24-h
BP variability with cognitive perfor-
mance in either group. In addition, we
found no significant associations of day-
time and nighttime SBP with cognitive
performance, except for a linear associ-
ation between daytime SBP and infor-
mation processing speed in individuals
with diabetes. Finally, dipping status
was associated with some measures of
cognitive performance in both individu-
als with and without diabetes, but no
clear pattern could be found in these
associations.
U-shaped relationships between DBP
and cognitive function have been shown
previously (14,15). Moreover, both low
and high office DBP and MAP, but not
SBP and PP, have been associated with
cognitive impairment 20 years later (15).
Explanations for this U-shaped relation-
shipmay include antihypertensivemedica-
tion use, arterial stiffness, atherosclerosis,
and/or cerebral autoregulation.
In individuals untreated for hyper-
tension, a high office DBP has been as-
sociated with hippocampal atrophy,
whereas in those treated for hy-
pertension, a low DBP has been asso-
ciated with more hippocampal and
amygdalar atrophy (33). This may indi-
cate that antihypertensive medication
use is involved in the association be-
tween DBP and cognitive performance.
However, in our study, the U-shaped as-
sociations in the group with diabetes
were attenuated only slightly and




speed Immediate word recall Delayed word recall
Response
inhibition#
Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2
No diabetes
24-h SBP§
Linear 0.0027 0.0041 0.0348 0.0356 0.0206 0.0391 0.0075 0.0087 20.0005 20.0006
24-h DBP§
Linear 20.0013 0.0011 0.0485 0.0514 20.0042 0.0338 20.0035 0.0030 0.0000 20.0003
Diabetes
24-h SBP§
Linear 20.0034 20.0043 20.0700 20.0846 0.0356 0.0329 0.0103 0.0091 0.0008 0.0014
24-h DBP
Linear 0.0190 0.0160 0.0235 0.0188 0.1361 0.1062 0.0512 0.0556 20.0024 20.0019
Quadratic 20.0014 20.0007 20.0314** 20.0267** 20.0253** 20.0180* 20.0085** 20.0076** 0.0004* 0.0003
For global cognitive functioning, information processing speed, and immediate and delayedword recall, a higher score indicates better performance,
and for response inhibition, a lower score indicates better performance. Model 1, adjustment for age, sex, and educational level; model 2, model 1 +
adjustment for smoking status, alcohol consumption, waist circumference, total cholesterol-to-HDL cholesterol ratio, triglyceride level,
antihypertensive medication use, lipid-modifying medication use, eGFR, cardiovascular disease, and depression. §For these associations, the
quadratic term was not significantly associated with any cognitive measure and was therefore dropped from the models. #Scores are log
transformed. *P , 0.05. **P , 0.01.
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remained significant when antihyperten-
sivemedication usewas added separately
to the model in addition to age, sex, and
educational level (data not shown).
Another explanationmay involve arte-
rial stiffening, which is increased in indi-
viduals with type 2 diabetes (34),
decreases DBP (35), and, together with
atherosclerosis (36), may cause hypoper-
fusion of the brain, resulting in a decline
in cognitive functions. However, in our
study, higher 24-h PP was not related
to information processing speed or
memory, arguing against the possibility
that arterial stiffening (which typically
increases PP) explains our results.
Finally, cerebral autoregulation may
be involved in the U-shaped relationship
between 24-h DBP and cognitive perfor-
mance. Under normal conditions, cere-
bral blood flow is kept constant across a
wide range of MAP (60–150 mmHg) by
cerebral autoregulation, which means
that arterioles in the brain constrict
when SBP rises and dilate when BP falls
(37,38). However, in individuals with
type 2 diabetes, the ability to dilate
blood vessels may be decreased or
even lost (39), which may be attribut-
able to cerebral small vessel disease
(39) or cardiovascular autonomic neu-
ropathy (40). When autoregulation is
lost, cerebral blood flow becomes de-
pendent on the MAP in a linear fashion
(41), and thus decline in BP can lead to
hypoperfusion of the brain and conse-
quently cognitive decline. Our finding
that a low 24-h MAP was associated
with decreased cognitive performance,
particularly information processing
speed, in individuals with diabetes fits
well with this hypothesis, although this
has to be confirmed by future (longitu-
dinal) studies. In addition, orthostatic
hypotension, which has been associated
with diabetes (42), may have an impact
on cognitive function (43), possibly by re-
current drops in (cerebral) BP. As data on
cardiovascular autonomic neuropathy
were not available, we could not further
explore the role of autonomic neuropa-
thy in the association of 24-h BP with
cognition.
In the current study, a high DBP was
also associated with poorer cognitive
performance in participants with diabe-
tes. Previous research has already shown
that in individuals with type 2 diabetes, a
higher DBP, but not SBP, is associated
with cognitive decline (44), and that cog-
nitive impairment is associated with ce-
rebral small vessel disease (45).
Furthermore, high DBP has shown to be
an independent predictor of white mat-
ter hyperintensity progression (46) and
hippocampal atrophy (33). In view of
these considerations, it may be hypothe-
sized that a high DBP leads to cognitive
impairment through the development of
cerebral small vessel disease. Individuals
with type 2 diabetes may then be partic-
ularly susceptible to the effects of high
Figure 1—Interaction of nonlinear (quadratic) 24-h DBP (mmHg) and diabetes (solid, no diabetes; dash, diabetes) for information processing speed
(number of digits) (A), immediate word recall (number of words) (B), and delayed word recall (number of words) (C).
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DBP as they are already at risk to develop
cerebral small vessel disease and cogni-
tive impairment.
We could not detect a clear pattern in
the associations of nondipping and ex-
treme dipping with aspects of cognitive
performance in participants with and
without diabetes. Previous studies, al-
though not stratified by diabetes status,
have shown inconsistent results with re-
gard to the association of dipping param-
eters with cognitive performance and
cerebrovascular damage (11,47,48).
These inconsistencies may be due to dif-
ferences in age, hypertensive status, and
duration of hypertension and treatment
history, of which reliable information can
be difficult to obtain (47). Stronger asso-
ciations may be found in older individuals
with a long history of hypertension, and
especially in older individuals with diabe-
tes, who may have an increased risk of
developing cognitive impairment. How-
ever, we acknowledge that our sample
sizes of the nondipping and extreme dip-
ping groupswere quite small, which limits
the power to find significant associations.
Finally, it has been suggested that re-
peated ABPM may increase the accu-
racy of dipper status assessment (49)
and may be a better predictor of cogni-
tive performance.
Furthermore, in contrast to (prospec-
tive) studies on associations between BP
variability and cardiovascular complica-
tions (50), we did not find clear associa-
tions of BP variability with cognitive
functions. Although effects of BP variabil-
ity on the heartmay differ from effects on
the brain, we may have failed to find as-
sociations because of the relatively young
age of our sample and because the cross-
sectional design did not allow us to exam-
ine effects of BP variability on cognitive
change over time.
To the best of our knowledge, this is
the first study to examine both linear
and nonlinear (quadratic) associations
between ABPM and multiple cognitive
tests stratified by diabetes status. In
one previous study (51), the (inverse) as-
sociation between 24-h DBP and cogni-
tive performance was stratified by
diabetes status in a subanalysis (stratifi-
cation did not seem to alter the relation-
ship). However, this study was only
performed in older men and lacked
data on memory performance, and asso-
ciations of nondipping with cognitive
functions were not stratified by diabetes
status. Another strength of our study is
that we were able to adjust for a wide
range of potential confounders.
Our study is not without limitations.
Due to the cross-sectional design, we
were unable to examine temporality of
effects, let alone causal relationships. Al-
though we used tests for cognitive do-
mains that have been shown to be
sensitive to effects of hypertension (52),
it is possible thatwemissed subtle effects
of BP on cognitive functions in the group
without diabetes, which was healthier
and younger. Such effects may become
manifest in longitudinal data where par-
ticipants show more advanced stages of
cognitive aging (52). In addition, we did
not have data on glucose levels at the
time of the cognitive assessment. There-
fore, we cannot exclude the possibility
that cognitive test results in individuals
with diabetes were influenced by rela-
tively high or low glucose levels, although
this should be considered part of the di-
abetic condition. Furthermore, we could
not examine the potential confounding
role of sleep apnea, which is more fre-
quent in individuals with diabetes, in the
associations of 24-h DBP with cognitive
functions. Last, we did not have brain im-
aging data to examine potential mecha-
nisms, e.g., cerebral small vessel disease,
which may be involved in the association
between DBP and cognitive decline.
In conclusion, this study shows that
both low and high 24-h DBP are associ-
ated with poorer performance on tests
for information processing speed and
memory in individuals with type 2 dia-
betes, but not in those without diabe-
tes. These results suggest that not only
high BP but also low BP levels may in-
crease the risk of cognitive impairment
in individuals with type 2 diabetes,
which may be important to consider in
the therapeutic management of (dia-
stolic) BP levels in those individuals.
Monitoring of both BP levels and cogni-
tive performance seems important in in-
dividuals with type 2 diabetes. Future
(longitudinal) studies should focus on
causality and underlying mechanisms.
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